Marketed drugs used for the management of hypercholesterolemia as anticancer armament.

ABSTRACT: The design of novel pharmacologic agents as well as their approval for sale in markets all over the world is a tedious and pricey process. Inevitably, oncologic patients commonly experience unwanted effects of new anticancer drugs, while the acquisition of clinical experience for these drugs is largely based on doctor-patient partnership which is not always effective. The repositioning of marketed non-antineoplastic drugs that hopefully exhibit anticancer properties into the field of oncology is a challenging option that gains ground and attracts preclinical and clinical research in an effort to override all these hindrances and minimize the risk for reduced efficacy and/or personalized toxicity. This review aims to present the anticancer properties of drugs used for the management of hype

SUBMITTER: Papanagnou P 

PROVIDER: S-EPMC5598753 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature